Trump Administration’s Discount Drug Platform TrumpRx Launches Tonight. Here’s What to Know

The Trump administration says its new discount prescription-drug platform, TrumpRx, will go live Thursday, Feb. 5, at 7 p.m.

President Donald Trump is expected to unveil the site alongside Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz and Airbnb co-founder Joe Gebbia, who oversees the National Design Studio, the team that designs federal websites.

In a post on X, press secretary Karoline Leavitt called TrumpRx “a state of the art website for Americans consumers to purchase low cost prescription drugs,” adding that the rollout is a “historic announcement” that will save consumers money.

According to The New York Times, TrumpRx is not designed to prescribe medications or sell them directly. Instead, it functions as a portal: patients who already have a prescription can use the platform to navigate to a medication’s designated website to purchase it.

The administration has reached agreements with at least 16 manufacturers, NBC News reported. While a complete list of medicines has not been released, drugs expected to be available through TrumpRx include Januvia (Merck), Repatha, and the GLP-1 weight-loss medications Wegovy (Novo Nordisk) and Zepbound (Eli Lilly), per NBC News.

Officials have previously promoted a deal offering certain GLP-1 medications for as low as $149 per month. Other prices cited by The New York Times vary widely, from $16 a month for the blood thinner Plavix to $2,425 for Epclusa, a 12-week hepatitis C treatment.

The administration has also pointed to a “most favored nation” approach—arguing the U.S. should not pay more than other countries for the same medications. Reuters has reported that U.S. patients can pay up to three times more than patients in other developed nations for the same drugs. However, NPR, citing data from drug price research firm 46 Brooklyn, reported that the 16 participating companies—and others—raised prices in January.

Experts told multiple outlets that TrumpRx could be most helpful for people paying cash out of pocket, while offering limited value for many patients with private insurance or Medicaid, as NBC News reported in January.

“TrumpRx might support access and affordability for a very small number of people,” Rena Conti, an associate professor at Boston University’s Questrom School of Business, told CNN.

“There’s no clear advantage for most people to use TrumpRx to purchase their medications,” Juliette Cubanski, deputy director of the program on Medicare Policy at KFF, told NBC News.